Tumor-specific surface marker-independent targeting of tumors through nanotechnology and bioorthogonal glycochemistry. Hyun H, Sun B, Yazdimamaghani M, Wielgus A, et al. J Clin Invest 2025;135:e184964.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hyun H, Sun B, Yazdimamaghani M, Wielgus A, et al. Tumor-specific surface marker-independent targeting of tumors through nanotechnology and bioorthogonal glycochemistry. J Clin Invest 2025;135:e184964.
PMID: 40067370